Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.46 |
| ▸ | MPL | P40238 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175670 | 0.85 | EGFR (0.68) | EGFRERBB3CDK4TNNI3KMPL | |
| SCHEMBL2173971 | 0.84 | EGFR (0.72) | EGFRERBB3CDK4TNNI3KGBA1 | |
| SCHEMBL2176919 | 0.84 | EGFR (0.71) | EGFRERBB3CDK4TNNI3KGBA1 | |
| SCHEMBL2175110 | 0.81 | MEN1 (0.72) | EGFRERBB3CDK4TNNI3KGBA1 | |
| SCHEMBL2175771 | 0.79 | EGFR (0.54) | EGFRHPGDTNNI3KMEN1KMT2A | |
| SCHEMBL2177484 | 0.79 | EGFR (0.57) | EGFRERBB3SCN9ACDK4TNNI3K | |
| SCHEMBL2175687 | 0.79 | EGFR (0.57) | EGFRERBB3MEN1KMT2A | |
| SCHEMBL2174704 | 0.76 | EGFR (0.67) | EGFRERBB3CDK4 | |
| SCHEMBL4760023 | 0.76 | EGFR (0.60) | EGFRERBB3MPLMEN1KMT2A | |
| SCHEMBL12482572 | 0.76 | JAK2 (0.62) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519501-B1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | UNIV WIEN TECH (AT) | 2015-04-22 | — | — | EP | claimed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | claimed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | claimed |
| EP-2519501-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | Technische Universität Wien (AT) | 2012-11-07 | — | — | EP | claimed |
| WO-2011079343-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TECHNISCHE UNIVERSITAET WIEN (AT) | 2011-07-07 | — | — | WO | claimed |
| EP-2519501-B1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | UNIV WIEN TECH (AT) | 2015-04-22 | — | — | EP | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| EP-2519501-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | Technische Universität Wien (AT) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011079343-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TECHNISCHE UNIVERSITAET WIEN (AT) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011079343-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TECHNISCHE UNIVERSITAET WIEN (AT) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TNNI3, TNNT2, PROX1 | EGFR 4266/4885ERBB3 4256/4885SCN9A 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.